Sign Out
Each pre-filled pen contains 150 mg risankizumab in 1 mL solution.
Risankizumab is a humanised immunoglobulin G1 (IgG1) monoclonal antibody selective to the interleukin (IL)-23 protein produced in Chinese Hamster Ovary cells using recombinant DNA technology.
SKYRIZI 150 mg/mL contains less than 1 mmol sodium (23 mg) per 150 mg dose, i.e., essentially 'sodium-free'.
Excipients/Inactive Ingredients: Sodium acetate trihydrate, Acetic acid, Trehalose dihydrate, Polysorbate 20, Water for injections.
